share_log

Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388 From Johnson & Johnson For A One Time Payment Of $85M; Announces Private Placement Financing Of $240M

Cidara Therapeutics Reacquires Global Development And Commercial Rights To CD388 From Johnson & Johnson For A One Time Payment Of $85M; Announces Private Placement Financing Of $240M

Cidara Therapeutics 一次性付款 8500 萬美元從強生公司手中收購 CD388 的全球開發和商業權；宣佈私募融資 2.4 億美元
Benzinga ·  04/25 04:47
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial
-由RA Capital Management牽頭的2.4億美元私募融資，貝恩資本生命科學以及BVF Partners和Canaan Partners大量參與，爲2b期臨床試驗提供資金
- CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment
-正在開發對所有甲型和乙型流感菌株具有活性的 CD388，用於暴露前預防治療
- Company to host business strategy update conference call and webcast today at 4:30 PM ET
-公司將於美國東部時間今天下午 4:30 主持業務戰略更新電話會議和網絡直播
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients...
聖地亞哥，2024年4月24日（GLOBE NEWSWIRE）——生物技術...
登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論